Constellation Pharmaceuticals Inc. (CNST) and CASI Pharmaceuticals Inc. (NASDAQ:CASI) Comparing side by side

Both Constellation Pharmaceuticals Inc. (NASDAQ:CNST) and CASI Pharmaceuticals Inc. (NASDAQ:CASI) are Biotechnology companies, competing one another. We will contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Constellation Pharmaceuticals Inc. N/A 0.00 59.92M -2.14 0.00
CASI Pharmaceuticals Inc. N/A 0.00 27.47M -0.30 0.00

Table 1 demonstrates Constellation Pharmaceuticals Inc. and CASI Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 provides us Constellation Pharmaceuticals Inc. and CASI Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Constellation Pharmaceuticals Inc. 0.00% 0% 0%
CASI Pharmaceuticals Inc. 0.00% -30.7% -28.7%


Constellation Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 12.5 and 12.5 respectively. The Current Ratio and Quick Ratio of its competitor CASI Pharmaceuticals Inc. are 14.6 and 14.6 respectively. CASI Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Constellation Pharmaceuticals Inc.

Analyst Recommendations

In next table is delivered Constellation Pharmaceuticals Inc. and CASI Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Constellation Pharmaceuticals Inc. 0 0 1 3.00
CASI Pharmaceuticals Inc. 0 0 1 3.00

Constellation Pharmaceuticals Inc.’s consensus target price is $18, while its potential upside is 36.47%. Competitively CASI Pharmaceuticals Inc. has an average target price of $7, with potential upside of 121.52%. The information presented earlier suggests that CASI Pharmaceuticals Inc. looks more robust than Constellation Pharmaceuticals Inc. as far as analyst belief.

Insider and Institutional Ownership

Constellation Pharmaceuticals Inc. and CASI Pharmaceuticals Inc. has shares held by institutional investors as follows: 82.4% and 21.5%. Insiders held 0.1% of Constellation Pharmaceuticals Inc. shares. Competitively, 18.2% are CASI Pharmaceuticals Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Constellation Pharmaceuticals Inc. -7.25% 38.04% 73.87% 3.21% 0% 148.88%
CASI Pharmaceuticals Inc. -8.89% -5.2% -15.9% -52.67% -5.48% -18.41%

For the past year Constellation Pharmaceuticals Inc. has 148.88% stronger performance while CASI Pharmaceuticals Inc. has -18.41% weaker performance.


CASI Pharmaceuticals Inc. beats on 4 of the 7 factors Constellation Pharmaceuticals Inc.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. In addition, its pipeline includes 2ME2 (2-methoxyestradial), an orally active compound that has antiproliferative, antiangiogenic, and anti-inflammatory properties. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.